1086 related articles for article (PubMed ID: 26175499)
1. Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.
Lillyblad MP
Ann Pharmacother; 2015 Nov; 49(11):1237-51. PubMed ID: 26175499
[TBL] [Abstract][Full Text] [Related]
2. Sacubitril/Valsartan (LCZ696) in Heart Failure.
Khder Y; Shi V; McMurray JJV; Lefkowitz MP
Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
[TBL] [Abstract][Full Text] [Related]
3. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.
Marques da Silva P; Aguiar C
Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335
[TBL] [Abstract][Full Text] [Related]
4. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
5. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau J; Shi VC; Solomon SD; Swedberg K; Zile MR;
Eur J Heart Fail; 2013 Sep; 15(9):1062-73. PubMed ID: 23563576
[TBL] [Abstract][Full Text] [Related]
6. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
Ansara AJ; Kolanczyk DM; Koehler JM
J Clin Pharm Ther; 2016 Apr; 41(2):119-27. PubMed ID: 26992459
[TBL] [Abstract][Full Text] [Related]
7. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
Jhund PS; McMurray JJ
Heart; 2016 Sep; 102(17):1342-7. PubMed ID: 27207980
[TBL] [Abstract][Full Text] [Related]
8. [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure].
Di Tano G; Di Lenarda A; Gabrielli D; Aspromonte N; De Maria R; Frigerio M; Iacoviello M; Mortara A; Murrone A; Nardi F; Oliva F; Pontremoli R; Scherillo M; Senni M; Urbinati S; Gulizia MM
G Ital Cardiol (Rome); 2018 Oct; 19(10):568-590. PubMed ID: 30281045
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W
J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961
[TBL] [Abstract][Full Text] [Related]
10. Sacubitril/valsartan (LCZ696) for the treatment of heart failure.
Gori M; Senni M
Expert Rev Cardiovasc Ther; 2016; 14(2):145-53. PubMed ID: 26642078
[TBL] [Abstract][Full Text] [Related]
11. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
12. Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives.
Yandrapalli S; Andries G; Biswas M; Khera S
Vasc Health Risk Manag; 2017; 13():369-382. PubMed ID: 29042791
[TBL] [Abstract][Full Text] [Related]
13. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
King JB; Shah RU; Bress AP; Nelson RE; Bellows BK
JACC Heart Fail; 2016 May; 4(5):392-402. PubMed ID: 27039128
[TBL] [Abstract][Full Text] [Related]
15. Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan.
Liu RC
Am J Cardiovasc Drugs; 2018 Dec; 18(6):473-482. PubMed ID: 29850980
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
Kobalava Z; Kotovskaya Y; Averkov O; Pavlikova E; Moiseev V; Albrecht D; Chandra P; Ayalasomayajula S; Prescott MF; Pal P; Langenickel TH; Jordaan P; Rajman I
Cardiovasc Ther; 2016 Aug; 34(4):191-8. PubMed ID: 26990595
[TBL] [Abstract][Full Text] [Related]
17. The Role of Neprilysin Inhibitors in Cardiovascular Disease.
Mills J; Vardeny O
Curr Heart Fail Rep; 2015 Dec; 12(6):389-94. PubMed ID: 26466607
[TBL] [Abstract][Full Text] [Related]
18. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
Nougué H; Pezel T; Picard F; Sadoune M; Arrigo M; Beauvais F; Launay JM; Cohen-Solal A; Vodovar N; Logeart D
Eur J Heart Fail; 2019 May; 21(5):598-605. PubMed ID: 30520545
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System.
Han J; Chung F; Nguyen QL; Mody FV; Jackevicius CA
Pharmacotherapy; 2019 Nov; 39(11):1053-1059. PubMed ID: 31498903
[TBL] [Abstract][Full Text] [Related]
20. Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review.
King JB; Bress AP; Reese AD; Munger MA
Pharmacotherapy; 2015 Sep; 35(9):823-37. PubMed ID: 26406774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]